Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
| ▸ | GNG2 | P59768 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28046681 | 1.00 | CA1 (0.54) | CA1CA2MAOATSHRTUBB4A | |
| Hydrochloric Acid SCHEMBL17910635 | 0.98 | CA1 (0.53) | CA1CA2MAOATSHRTUBB4A | |
| SCHEMBL1748257 | 0.89 | CHRNA7 (0.48) | CA1CA2MAOATSHRCHRNA7 | |
| SCHEMBL2466599 | 0.86 | MAOA (0.55) | MAOATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17041217 | 0.86 | CYP19A1 (0.53) | CA1CA2TUBB4ATUBBTUBA3C | |
| Hydrochloric Acid SCHEMBL5969887 | 0.84 | MAOA (0.56) | MAOATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7929913 | 0.80 | CYP3A4 (0.48) | CA1CA2MAOATSHRCA7 | |
| SCHEMBL7936406 | 0.80 | CYP3A4 (0.48) | CA1CA2MAOATSHRCA7 | |
| SCHEMBL8276942 | 0.80 | CYP3A4 (0.48) | CA1CA2MAOATSHRCA7 | |
| Hydrochloric Acid SCHEMBL15664148 | 0.78 | CYP3A4 (0.46) | CA1CA2MAOATSHRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106431939-A | Method for synthesizing R type aminoindane | 陈永军 | 2017-02-22 | — | — | CN | claimed |
| CN-105152944-A | Preparation method of R-5, 6-dimethoxy-1-aminoindane | WU LING | 2015-12-16 | — | — | CN | claimed |
| CN-105111095-A | Method for preparing S-5, 6-dimethoxy-1-aminoindane | WU LING | 2015-12-02 | — | — | CN | claimed |
| CN-105473575-B | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | 爱杜西亚药品有限公司 | 2017-11-24 | — | — | CN | disclosed |
| EP-3133059-A1 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2017-02-22 | — | — | EP | disclosed |
| CN-106431939-A | Method for synthesizing R type aminoindane | 陈永军 | 2017-02-22 | — | — | CN | disclosed |
| CN-106431939-A | Method for synthesizing R type aminoindane | 陈永军 | 2017-02-22 | — | — | CN | disclosed |
| CN-105473575-A | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2016-04-06 | — | — | CN | disclosed |
| CN-105152944-A | Preparation method of R-5, 6-dimethoxy-1-aminoindane | WU LING | 2015-12-16 | — | — | CN | disclosed |
| CN-105152944-A | Preparation method of R-5, 6-dimethoxy-1-aminoindane | WU LING | 2015-12-16 | — | — | CN | disclosed |
| CN-105111095-A | Method for preparing S-5, 6-dimethoxy-1-aminoindane | WU LING | 2015-12-02 | — | — | CN | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
| EP-0882046-A1 | QUINOLONES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030999-A1 | QUINOLONES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
| WO-1996036596-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
| EP-0144235-A2 | N6-(1- and 2-benzocycloalkyl) adenosines, pharmaceutical compositions comprising the same and a process for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | CA1 2487/4885CA2 1619/4885MAOA 398/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | CA1 2490/4885CA2 692/4885MAOA 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.